Welcome to our dedicated page for DURECT SEC filings (Ticker: DRRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Finding the trial data that could shift DURECT’s valuation shouldn’t feel like combing through a lab notebook. Biotech SEC filings are dense—hundreds of pages of clinical results, licensing clauses, and risk factors. DURECT Corporation’s 10-K alone details epigenetic therapy science, cash burn projections, and FDA designations that move the stock.
Stock Titan turns that complexity into clarity. Our AI delivers DURECT SEC filings explained simply—from the DURECT annual report 10-K simplified to every DURECT quarterly earnings report 10-Q filing. Need real-time alerts? We stream DURECT Form 4 insider transactions real-time so you can spot confidence buys or option exercises before the market reacts. Each document arrives with an AI-powered summary, key-metric extractions, and plain-language answers to questions like “What does the latest 8-K say about the AHFIRM trial?”
Here’s what you can unlock:
- Pipeline progress and cash-runway analysis inside 10-Qs—perfect for DURECT earnings report filing analysis
- DURECT insider trading Form 4 transactions mapped against clinical milestones to monitor sentiment
- Instant explanations of any DURECT 8-K material events explained—from FDA feedback to licensing deals
- Compensation metrics in the DURECT proxy statement executive compensation section, tied to trial success hurdles
Whether you’re understanding DURECT SEC documents with AI for the first time or scanning DURECT executive stock transactions Form 4 before earnings, Stock Titan provides complete coverage and professional insight—no PDF diving required.
DURECT Corp. (ticker DRRX) has entered into a definitive Agreement and Plan of Merger dated 28 Jul 2025 with Bausch Health Americas, Inc. Under the agreement, wholly owned subsidiary BHC Lyon Merger Sub will launch a cash tender offer to acquire all outstanding DURECT common shares, followed by a back-end merger. This Schedule 14D-9C is only an early communication; the Schedule TO (offer documents) and full 14D-9 (board recommendation) have not yet been filed. Consequently, no per-share consideration, transaction value, or expected closing date is disclosed here. Completion is conditioned on minimum share tender, regulatory approvals and other customary provisions. The filing incorporates the company’s 8-K of 29 Jul 2025 and reiterates extensive forward-looking-statement cautions, highlighting risks such as potential termination, litigation, integration challenges and disruption to ongoing operations.
DURECT Corp. (DRRX) executed a definitive Agreement & Plan of Merger with Bausch Health Americas on 28-Jul-2025. A wholly-owned subsidiary of Bausch will launch a tender offer by 11-Aug-2025 to acquire all outstanding DRRX shares for $1.75 cash per share plus one non-tradable contingent value right (CVR). Each CVR entitles holders to share, pro rata, in two milestone cash payments of up to $350 million aggregate: $100 million upon ≥$500 million worldwide annual net sales of larsucosterol (Milestone #1) and $250 million upon ≥$1 billion (Milestone #2), in either case before the earlier of 10 years after first U.S. commercial sale or 31-Dec-2045.
The offer is conditioned on >50% of shares (on a fully diluted basis) being tendered, customary regulatory clearances and absence of a Company Material Adverse Effect; no financing condition applies. Following successful completion, a short-form merger under DGCL §251(h) will close, with DURECT surviving as a Bausch subsidiary and all untendered shares converted into the same consideration. The board unanimously approved the deal and recommends shareholders tender. The agreement contains non-solicitation covenants, a 3.5 million termination fee payable to Bausch under specified scenarios, and an outside date of 28-Oct-2025 (extendable to 28-Nov-2025 for regulatory reasons). Outstanding options will be cancelled for cash (for in-the-money options) and potential retention bonuses linked to the milestones; warrants will follow their terms. A retention plan for key employees and a joint press release (Ex. 99.1) were also disclosed.
FAQ
What is the current stock price of DURECT (DRRX)?
What is the market cap of DURECT (DRRX)?
